Supplementary Table 1 from HIC1 Silencing in Triple-Negative Breast Cancer Drives Progression Through Misregulation of LCN2

Guangcun Cheng,Xueqing Sun,Jinglong Wang,Gang Xiao,Xiumin Wang,Xuemei Fan,Lidong Zu,Mingang Hao,Qing Qu,Yan Mao,Yunjing Xue,Jianhua Wang

DOI: https://doi.org/10.1158/0008-5472.22401657

2023-01-01

Abstract:PDF file - 116K, Correlation between expression of HIC1 and clinical pathological features in tissue microarrays.

What problem does this paper attempt to address?

Supplementary Table 2 from HIC1 Silencing in Triple-Negative Breast Cancer Drives Progression through Misregulation of LCN2

Guangcun Cheng,Xueqing Sun,Jinglong Wang,Gang Xiao,Xiumin Wang,Xuemei Fan,Lidong Zu,Mingang Hao,Qing Qu,Yan Mao,Yunjing Xue,Jianhua Wang

DOI: https://doi.org/10.1158/0008-5472.22401654

2023-01-01

Abstract:<p>PDF file - 118K, Serum levels of LCN2 in breast cancer patients.</p>
Supplementary Figure 1 from HIC1 Silencing in Triple-Negative Breast Cancer Drives Progression Through Misregulation of LCN2

Guangcun Cheng,Xueqing Sun,Jinglong Wang,Gang Xiao,Xiumin Wang,Xuemei Fan,Lidong Zu,Mingang Hao,Qing Qu,Yan Mao,Yunjing Xue,Jianhua Wang

DOI: https://doi.org/10.1158/0008-5472.22401690

2023-01-01

Abstract:PDF file - 623K, Effects of restoring HIC1 expression in MDA-468 cells.
Supplementary Figure 3 from HIC1 Silencing in Triple-Negative Breast Cancer Drives Progression Through Misregulation of LCN2

Guangcun Cheng,Xueqing Sun,Jinglong Wang,Gang Xiao,Xiumin Wang,Xuemei Fan,Lidong Zu,Mingang Hao,Qing Qu,Yan Mao,Yunjing Xue,Jianhua Wang

DOI: https://doi.org/10.1158/0008-5472.22401684

2023-01-01

Abstract:PDF file - 141K, HIC1 and LCN2 do not affect epithelial-mesenchymal transition (EMT).
Supplementary Figure 8 from HIC1 Silencing in Triple-Negative Breast Cancer Drives Progression Through Misregulation of LCN2

Guangcun Cheng,Xueqing Sun,Jinglong Wang,Gang Xiao,Xiumin Wang,Xuemei Fan,Lidong Zu,Mingang Hao,Qing Qu,Yan Mao,Yunjing Xue,Jianhua Wang

DOI: https://doi.org/10.1158/0008-5472.22401669.v1

2023-01-01

Abstract:PDF file - 344K, Endogenous HIC1 knockdown promotes cell migration and invasion in MCF-10A cells.
Supplementary Figure 4 from HIC1 Silencing in Triple-Negative Breast Cancer Drives Progression Through Misregulation of LCN2

Guangcun Cheng,Xueqing Sun,Jinglong Wang,Gang Xiao,Xiumin Wang,Xuemei Fan,Lidong Zu,Mingang Hao,Qing Qu,Yan Mao,Yunjing Xue,Jianhua Wang

DOI: https://doi.org/10.1158/0008-5472.22401681

2023-01-01

Abstract:PDF file - 77K, LCN2 does not affect MMP9 expression.
Supplementary Figure 7 from HIC1 Silencing in Triple-Negative Breast Cancer Drives Progression Through Misregulation of LCN2

Guangcun Cheng,Xueqing Sun,Jinglong Wang,Gang Xiao,Xiumin Wang,Xuemei Fan,Lidong Zu,Mingang Hao,Qing Qu,Yan Mao,Yunjing Xue,Jianhua Wang

DOI: https://doi.org/10.1158/0008-5472.22401672

2023-01-01

Abstract:PDF file - 132K, LCN2 does not affect PTEN activity.
Supplementary Figure 2 from HIC1 Silencing in Triple-Negative Breast Cancer Drives Progression Through Misregulation of LCN2

Guangcun Cheng,Xueqing Sun,Jinglong Wang,Gang Xiao,Xiumin Wang,Xuemei Fan,Lidong Zu,Mingang Hao,Qing Qu,Yan Mao,Yunjing Xue,Jianhua Wang

DOI: https://doi.org/10.1158/0008-5472.22401687

2023-01-01

Abstract:PDF file - 131K, LCN2 does not affect ERK and NF-kB pathways.
Supplementary Figure 5 from HIC1 Silencing in Triple-Negative Breast Cancer Drives Progression Through Misregulation of LCN2

Guangcun Cheng,Xueqing Sun,Jinglong Wang,Gang Xiao,Xiumin Wang,Xuemei Fan,Lidong Zu,Mingang Hao,Qing Qu,Yan Mao,Yunjing Xue,Jianhua Wang

DOI: https://doi.org/10.1158/0008-5472.22401678

2023-01-01

Abstract:PDF file - 570K, LCN2 promotes lung metastasis in balb/c nude mice.
Supplementary Tables from LIMS1 Promotes Pancreatic Cancer Cell Survival under Oxygen–Glucose Deprivation Conditions by Enhancing HIF1A Protein Translation

Chongbiao Huang,Yang Li,Zengxun Li,Yang Xu,Na Li,Yi Ge,Jie Dong,Antao Chang,Tiansuo Zhao,Xiuchao Wang,Hongwei Wang,Shengyu Yang,Keping Xie,Jihui Hao,He Ren

DOI: https://doi.org/10.1158/1078-0432.22470555

2023-01-01

Abstract:7 Supplementary Tables: Supplementary Table S1. Association between LIMS1 expression and clinicopathological features of patients with PDAC. Supplementary Table S2. Association between LIMS1 mRNA expression and clinicopathological features of PDAC patients from TCGA. Supplementary Table S3. Cox's proportional hazards model analysis of prognostic factors in patients with pancreatic ductal adenocarcinoma (PDAC) Supplementary Table S4. Association between LIMS1 expression and clinicopathological features of patients with esophageal cancer. Supplementary Table S5. Association between LIMS1 expression and clinicopathological features of patients with lung adenocarcinoma. Supplementary Table S6. Main antibodies and reagents. Supplementary Table S7. Primers and oligonucleotides sequences.
Supplementary Figure 6 from HIC1 Silencing in Triple-Negative Breast Cancer Drives Progression Through Misregulation of LCN2

Guangcun Cheng,Xueqing Sun,Jinglong Wang,Gang Xiao,Xiumin Wang,Xuemei Fan,Lidong Zu,Mingang Hao,Qing Qu,Yan Mao,Yunjing Xue,Jianhua Wang

DOI: https://doi.org/10.1158/0008-5472.22401675

2023-01-01

Abstract:PDF file - 142K, The AKT signaling pathway is partly inactivated after NGALR knockdown.
Supplementary Table 2 from HIC1 Modulates Prostate Cancer Progression by Epigenetic Modification

Jianghua Zheng,Jinglong Wang,Xueqing Sun,Mingang Hao,Tao Ding,Dan Xiong,Xiumin Wang,Yu Zhu,Gang Xiao,Guangcun Cheng,Meizhong Zhao,Jian Zhang,Jianhua Wang

DOI: https://doi.org/10.1158/1078-0432.22450716.v1

2023-01-01

Abstract:PDF file - 53K, Part of genes regulated more than 2-fold in PC3HIC1 and C4-2BHIC1 cells comparison with the control
Supplementary Figure 2 from HIC1 Modulates Prostate Cancer Progression by Epigenetic Modification

Jun Zheng,Jinglong Wang,Xueqing Sun,Mingang Hao,Tao Ding,Dan Xiong,Xiumin Wang,Yan Zhu,Gang Xiao,Guangcun Cheng,Mengmeng Zhao,Jian Zhang,Jianhua Wang

DOI: https://doi.org/10.1158/1078-0432.22450740

2023-01-01

Abstract:PDF file - 488K, Effects in PCa cells after knockdown of expression of HIC1
Supplementary Figure from HMGN5 Escorts Oncogenic STAT3 Signaling by Regulating the Chromatin Landscape in Breast Cancer Tumorigenesis

Jiahui Mou,Meijun Huang,Feifei Wang,Xiaoding Xu,Hanqi Xie,Henglei Lu,Mingyang Li,Yu Li,Weiwen Kong,Jing Chen,Ying Xiao,Yiding Chen,Chaochen Wang,Jin Ren

DOI: https://doi.org/10.1158/1541-7786.22527890

2023-01-01

Abstract:Supplementary Figure from HMGN5 Escorts Oncogenic STAT3 Signaling by Regulating the Chromatin Landscape in Breast Cancer Tumorigenesis
Supplementary Figure 1 from HIC1 Modulates Prostate Cancer Progression by Epigenetic Modification

Jun Zheng,Jinglong Wang,Xueqing Sun,Mingang Hao,Tao Ding,Dan Xiong,Xiumin Wang,Yan Zhu,Gang Xiao,Guangcun Cheng,Mengmeng Zhao,Jian Zhang,Jianhua Wang

DOI: https://doi.org/10.1158/1078-0432.22450743.v1

2023-01-01

Abstract:PDF file - 416K, Methylation status of HIC1 promoter in plasma DNA from PCa patients and healthy controls.
Supplementary Figure 3 from HIC1 Modulates Prostate Cancer Progression by Epigenetic Modification

Jianghua Zheng,Jinglong Wang,Xueqing Sun,Mingang Hao,Tao Ding,Dan Xiong,Xiumin Wang,Yu Zhu,Gang Xiao,Guangcun Cheng,Meizhong Zhao,Jian Zhang,Jianhua Wang

DOI: https://doi.org/10.1158/1078-0432.22450737

2023-01-01

Abstract:PDF file - 904K, Restoring HIC1 expression prevents PCa metastasis by intracardiac and tail vein injections in BALB/c Nude mice
Identification of lncRNA Signature of Tumor-Infiltrating T Lymphocytes With Potential Implications for Prognosis and Chemotherapy of Head and Neck Squamous Cell Carcinoma

Liping Wang,Gui Yang,Guohong Liu,Yunbao Pan

DOI: https://doi.org/10.3389/fphar.2021.795205

IF: 5.6

2022-02-15

Frontiers in Pharmacology

Abstract:Purpose: We systematically analyzed HNSCC-infiltrating T lymphocytes lncRNAs (HILTlncRNAs) to assess their predictive value for the survival outcome and immunotherapy response of patients with anti-programmed death-1 (PD-1) therapy and to evaluate their predictive power to chemotherapeutic agents. Methods: HNSCC transcriptome and clinical information was obtained from The Cancer Genome Atlas (TCGA) database. Immunocell microarray data were obtained from the Gene Expression Omnibus (GEO) database. T-cell-specific lncRNAs were identified by differential expression analysis. Prognostic paired HILTlncRNAs (PHILTlncRNAs) were filtered and modeled by univariate cox, lasso and multivariate cox regression analysis. To construct lncRNA-miRNA-mRNA competitive endogenous RNA (ceRNA) regulatory networks, differentially expressed mRNAs in HNSCC patients were incorporated, microRNAs and differentially expressed mRNAs interacting with T-cell-specific lncRNAs were filtered out based on miRcode, miRDB, miRTarBase, and TargetScan databases. Results: 75 T-cell-specific lncRNAs and 9 prognostic PHILTlncRNAs were identified. Low-risk HNSCC patients had a better prognosis and significant immune cell infiltration, driving the immune response. Differential expression of RNA-binding proteins (RBPs), PD-1 and programmed cell death 1 ligand 1 (PD-L1) was demonstrated in the high and low risk groups of HNSCC patients. In the high risk group, high expression of PD-1 improved patient prognosis, whereas the opposite was observed in the low-risk group. The promoter methylation levels of two RBPs (DNMT1 and ZC3H12D) were decreased in HNSCC patients compared with normal samples, their expression levels were positively correlated with PD-1 and PD-L1 levels and T-cell infiltration. Finally, we screened the sensitivity of HNSCC patients to chemotherapeutic agents and found it differed between high and low risk groups. Conclusion: HILTlncRNAs provided a theoretical basis for immune targeted therapy and drug development.

pharmacology & pharmacy
Supplementary Tables 1-2 and Supplementary Figures S1-S5 and Legends from Suppression of the Growth and Invasion of Human Head and Neck Squamous Cell Carcinomas Via Regulating STAT3 Signaling and the Mir-21/Β-catenin Axis with HJC0152

Yu Wang,Sinan Wang,Yi‐Long Wu,Rong Yu,Zhaoqing Li,Xiaofeng Yao,Chao Zhang,Na Ye,Chao Jing,Jiabin Dong,Kailiang Zhang,Shuangqing Sun,Ming‐Hui Zhao,Wei Guo,Xin-Ping Qu,Yu Qiao,Haiying Chen,Lingping Kong,Rui Jin,Xudong Wang,Lun Zhang,Zhenhong Jia,Qiang Shen,Xuan Zhou

DOI: https://doi.org/10.1158/1535-7163.22507822.v1

2023-01-01

Abstract:Supplementary Table 1. List of primers and oligos used in this investigation; Supplementary Table 2 Primary antibodies used in this investigation; Supplementary Figure S1. HJC0152 exerts antitumor effect against HNSCC cell lines via regulating STAT3; Supplementary Figure S2. HJC0152 blocks nuclear translocation of p-STAT3 and β-catenin; Supplementary Figure S3. HJC0152 suppresses invasion and migration in HNSCC cell lines; Supplementary Figure S4. HJC0152 regulates the activity of miR-21/β-catenin axis; Supplementary Figure S5. VHL abrogation dramatically counteracts the impact of HJC0152 in vitro.
Supplementary Table 1 from A Regulatory Loop Involving miR-22, Sp1, and c-Myc Modulates CD147 Expression in Breast Cancer Invasion and Metastasis

Ling-Min Kong,Cheng-Gong Liao,Yang Zhang,Jing Xu,Yu Li,Wan Huang,Yi Zhang,Huijie Bian,Zhi-Nan Chen

DOI: https://doi.org/10.1158/0008-5472.22402862

2023-01-01

Abstract:PDF file - 75K, Oligonucleotide sequence of PCR primers and siRNA fragments.
Supplementary Materials and Methods, Supplementary Figures 1 Through 7, and Supplementary Tables 1 Through 6 from HSulf-1 Modulates FGF2- and Hypoxia-Mediated Migration and Invasion of Breast Cancer Cells

Ashwani Khurana,Peng Liu,Pasquale Mellone,Laura Lorenzon,Bruno Vincenzi,Kaustubh Datta,Bo Yang,Robert J. Linhardt,Wilma Lingle,Jeremy Chien,Alfonso Baldi,Viji Shridhar

DOI: https://doi.org/10.1158/0008-5472.22390554

2023-01-01

Abstract:Supplementary Materials and Methods. Figure S1: Quantitative Real-time PCR. Figure S2: MCF7 cells were transfected with HIF-1α siRNA oligos and control siRNA oligos before exposing them to hypoxia (3% oxygen) for indicated time intervals. Figure S3 : MTT assay was performed on MCF10DCIS batch clones after 24 hours of treatments as indicated. Figure S4: (A and B) pcDNA3.1 or pcDNA3.1 HSulf-1-myc/His plasmid transfected MCF10DCIS. Figure S5: K means cluster analysis of HSulf-1 expression with hypoxia signature genes as described in supplementary materials and methods. Figure S6: Kaplan-Meier survival analysis was performed to evaluate HSulf-1 mRNA expression levels with disease-free and overall patient survival. Figure S7: Proposed model. Table S1: Primers used for cloning, ChIP and siRNA oligos. Table S2: Patient Characteristics. Table S3: Chi-square statistical analysis of HSulf-1 and CAIX expression. Table S4: Prognostic factors in breast cancer cases compared with disease-free survival. Table S5: Prognostic factors in breast cancer cases compared with overall survival. Table S6: Characteristics of clinical parameters of breast cancer and HSulf-1 mRNA.
Hypermethylated in cancer 1(HIC1) suppresses non-small cell lung cancer progression by targeting interleukin-6/Stat3 pathway.

Xiumin Wang,Yingying Wang,Gang Xiao,Jinglong Wang,Lidong Zu,Mingang Hao,Xueqing Sun,Yujie Fu,Guohong Hu,Jianhua Wang

DOI: https://doi.org/10.18632/oncotarget.8734

2016-01-01

Oncotarget

Abstract:Non-small cell lung cancer (NSCLC), which accounts for more than 80% of lung cancers, is a leading cause of cancer mortality worldwide. However, the mechanism underlying its progression remains unclear. Here we found that HIC1 promoter was heavily methylated in NSCLC cell lines and tissues contributing to its low expression compared to normal controls. Restoring HIC1 expression inhibited migration, invasion and promoted inducible apoptosis of NSCLC cells. Notably, HIC1 is a tumor suppressor through inhibiting the transcription of IL-6 by sequence-specific binding on its promoter. Restoring IL-6 expression could partially rescue these phenotypes induced by HIC1 in vitro and in vivo. Mechanistic analyses show that autocrine secretion of IL-6 induced by loss of HIC1 activated STAT3 through IL-6/JAK pathway and was associated with NSCLC progression. The HIC1/IL-6 axis may serve as a prognostic biomarker and provide an attractive therapeutic target for NSCLC.

Supplementary Table 1 from HIC1 Silencing in Triple-Negative Breast Cancer Drives Progression Through Misregulation of LCN2

Supplementary Table 2 from HIC1 Silencing in Triple-Negative Breast Cancer Drives Progression through Misregulation of LCN2

Supplementary Figure 1 from HIC1 Silencing in Triple-Negative Breast Cancer Drives Progression Through Misregulation of LCN2

Supplementary Figure 3 from HIC1 Silencing in Triple-Negative Breast Cancer Drives Progression Through Misregulation of LCN2

Supplementary Figure 8 from HIC1 Silencing in Triple-Negative Breast Cancer Drives Progression Through Misregulation of LCN2

Supplementary Figure 4 from HIC1 Silencing in Triple-Negative Breast Cancer Drives Progression Through Misregulation of LCN2

Supplementary Figure 7 from HIC1 Silencing in Triple-Negative Breast Cancer Drives Progression Through Misregulation of LCN2

Supplementary Figure 2 from HIC1 Silencing in Triple-Negative Breast Cancer Drives Progression Through Misregulation of LCN2

Supplementary Figure 5 from HIC1 Silencing in Triple-Negative Breast Cancer Drives Progression Through Misregulation of LCN2

Supplementary Tables from LIMS1 Promotes Pancreatic Cancer Cell Survival under Oxygen–Glucose Deprivation Conditions by Enhancing HIF1A Protein Translation

Supplementary Figure 6 from HIC1 Silencing in Triple-Negative Breast Cancer Drives Progression Through Misregulation of LCN2

Supplementary Table 2 from HIC1 Modulates Prostate Cancer Progression by Epigenetic Modification

Supplementary Figure 2 from HIC1 Modulates Prostate Cancer Progression by Epigenetic Modification

Supplementary Figure from HMGN5 Escorts Oncogenic STAT3 Signaling by Regulating the Chromatin Landscape in Breast Cancer Tumorigenesis

Supplementary Figure 1 from HIC1 Modulates Prostate Cancer Progression by Epigenetic Modification

Supplementary Figure 3 from HIC1 Modulates Prostate Cancer Progression by Epigenetic Modification

Identification of lncRNA Signature of Tumor-Infiltrating T Lymphocytes With Potential Implications for Prognosis and Chemotherapy of Head and Neck Squamous Cell Carcinoma

Supplementary Tables 1-2 and Supplementary Figures S1-S5 and Legends from Suppression of the Growth and Invasion of Human Head and Neck Squamous Cell Carcinomas Via Regulating STAT3 Signaling and the Mir-21/Β-catenin Axis with HJC0152

Supplementary Table 1 from A Regulatory Loop Involving miR-22, Sp1, and c-Myc Modulates CD147 Expression in Breast Cancer Invasion and Metastasis

Supplementary Materials and Methods, Supplementary Figures 1 Through 7, and Supplementary Tables 1 Through 6 from HSulf-1 Modulates FGF2- and Hypoxia-Mediated Migration and Invasion of Breast Cancer Cells

Hypermethylated in cancer 1(HIC1) suppresses non-small cell lung cancer progression by targeting interleukin-6/Stat3 pathway.